Korean J Gastroenterol.  2022 Dec;80(6):247-253. 10.4166/kjg.2022.143.

Treatment of Acid-related Diseases Using Potassium-competitive Acid Blockers

• Choi YJ

• KMID: 2537095
• DOI: http://doi.org/10.4166/kjg.2022.143

Abstract

Proton pump inhibitors (PPIs) have several limitations to their efficacy including insufficient acid suppression, slow onset of action, and variable efficacy among patients due to CYP2C19 metabolism. Potassium-competitive acid blockers inhibit H + -K + -ATPase in a reversible and K + -competitive manner, are novel acid suppressive drugs with rapid onset of action, meal independence, and prolonged control of intragastric acidity compared to PPIs. Potassium-competitive acid blockers exhibited non-inferior therapeutic efficacies on reflux esophagitis, gastric ulcers, and Helicobacter pylori eradication. The review is focused on the unmet needs across the acid-related diseases and recent updates on clinical studies using vonoprazan and tegoprazan.

Keyword

Gastric acid; Gastroesophageal reflux; Peptic ulcer; Helicobacter pylori

Reference

1. Engevik AC, Kaji I, Goldenring JR. 2020; The physiology of the gastric parietal cell. Physiol Rev. 100:573–602. DOI: 10.1152/physrev.00016.2019. PMID: 31670611. PMCID: PMC7327232.

2. Piche T, Galmiche JP. 2005; Pharmacological targets in gastro-oesophageal reflux disease. Basic Clin Pharmacol Toxicol. 97:333–341. DOI: 10.1111/j.1742-7843.2005.pto_273.x. PMID: 16364047.

3. Oshima T, Miwa H. 2018; Potent potassium-competitive acid blockers: a new era for the treatment of acid-related diseases. J Neurogastroenterol Motil. 24:334–344. DOI: 10.5056/jnm18029. PMID: 29739175. PMCID: PMC6034668.

4. Jenkins H, Sakurai Y, Nishimura A, et al. 2015; Randomised clinical trial: safety, tolerability, pharmacokinetics and pharmacodynamics of repeated doses of TAK-438 (vonoprazan), a novel potassium-competitive acid blocker, in healthy male subjects. Aliment Pharmacol Ther. 41:636–648. DOI: 10.1111/apt.13121. PMID: 25707624. PMCID: PMC4654261.

5. Inatomi N, Matsukawa J, Sakurai Y, Otake K. 2016; Potassium-competitive acid blockers: advanced therapeutic option for acid-related diseases. Pharmacol Ther. 168:12–22. DOI: 10.1016/j.pharmthera.2016.08.001. PMID: 27514776.

6. Kagami T, Sahara S, Ichikawa H, et al. 2016; Potent acid inhibition by vonoprazan in comparison with esomeprazole, with reference to CYP2C19 genotype. Aliment Pharmacol Ther. 43:1048–1059. DOI: 10.1111/apt.13588. PMID: 26991399.

7. Yang E, Kim S, Kim B, et al. 2022; Night-time gastric acid suppression by tegoprazan compared to vonoprazan or esomeprazole. Br J Clin Pharmacol. 88:3288–3296. DOI: 10.1111/bcp.15268. PMID: 35146797. PMCID: PMC9305887.

8. Ashida K, Sakurai Y, Hori T, et al. 2016; Randomised clinical trial: vonoprazan, a novel potassium-competitive acid blocker, vs. lansoprazole for the healing of erosive oesophagitis. Aliment Pharmacol Ther. 43:240–251. DOI: 10.1111/apt.13461. PMID: 26559637. PMCID: PMC4738414.

9. Ashida K, Sakurai Y, Nishimura A, et al. 2015; Randomised clinical trial: a dose-ranging study of vonoprazan, a novel potassium-competitive acid blocker, vs. lansoprazole for the treatment of erosive oesophagitis. Aliment Pharmacol Ther. 42:685–695. DOI: 10.1111/apt.13331. PMID: 26201312. PMCID: PMC5014135.

10. Xiao Y, Zhang S, Dai N, et al. 2020; Phase III, randomised, double-blind, multicentre study to evaluate the efficacy and safety of vonoprazan compared with lansoprazole in Asian patients with erosive oesophagitis. Gut. 69:224–230. DOI: 10.1136/gutjnl-2019-318365. PMID: 31409606. PMCID: PMC6984055.

11. Lee KJ, Son BK, Kim GH, et al. 2019; Randomised phase 3 trial: tegoprazan, a novel potassium-competitive acid blocker, vs. esomeprazole in patients with erosive oesophagitis. Aliment Pharmacol Ther. 49:864–872. DOI: 10.1111/apt.15185. PMID: 30843245. PMCID: PMC6594096.

12. Cho YK, Kim JH, Kim HS, et al. 2023; Randomised clinical trial: comparison of tegoprazan and lansoprazole as maintenance therapy for healed mild erosive oesophagitis. Aliment Pharmacol Ther. 57:72–80. DOI: 10.1111/apt.17255. PMID: 36314172.

13. Jung HK, Tae CH, Song KH, et al. Korean Society of Neurogastroenterology and Motility. 2020 Seoul consensus on the diagnosis and management of gastroesophageal reflux disease. J Neurogastroenterol Motil. 2021; 27:453–481. Korean Society of Neurogastroenterology and Motility. DOI: 10.5056/jnm21077. PMID: 34642267. PMCID: PMC8521465.

14. Hoshino S, Kawami N, Takenouchi N, et al. 2017; Efficacy of vonoprazan for proton pump inhibitor-resistant reflux esophagitis. Digestion. 95:156–161. DOI: 10.1159/000456072. PMID: 28190016.

15. Fass R, Sifrim D. 2009; Management of heartburn not responding to proton pump inhibitors. Gut. 58:295–309. DOI: 10.1136/gut.2007.145581. PMID: 19136523.

16. Chey WD, Mody RR, Izat E. 2010; Patient and physician satisfaction with proton pump inhibitors (PPIs): are there opportunities for improvement? Dig Dis Sci. 55:3415–3422. DOI: 10.1007/s10620-010-1209-2. PMID: 20397047.

17. Shaker R, Castell DO, Schoenfeld PS, Spechler SJ. 2003; Nighttime heartburn is an under-appreciated clinical problem that impacts sleep and daytime function: the results of a Gallup survey conducted on behalf of the American Gastroenterological Association. Am J Gastroenterol. 98:1487–1493. DOI: 10.1111/j.1572-0241.2003.07531.x. PMID: 12873567.

18. Kinoshita Y, Sakurai Y, Shiino M, et al. Evaluation of the efficacy and safety of vonoprazan in patients with nonerosive gastroesophageal reflux disease: a phase iii, randomized, double-blind, placebo-controlled, multicenter study. Curr Ther Res Clin Exp. 2016; 81-82:1–7. DOI: 10.1016/j.curtheres.2016.12.001. PMID: 28119763. PMCID: PMC5238607.

19. Kinoshita Y, Sakurai Y, Takabayashi N, et al. 2019; Efficacy and safety of vonoprazan in patients with nonerosive gastroesophageal reflux disease: a randomized, placebo-controlled, phase 3 study. Clin Transl Gastroenterol. 10:e00101. DOI: 10.14309/ctg.0000000000000101. PMID: 31770139. PMCID: PMC6890278.

20. Gotoh Y, Ishibashi E, Honda S, et al. 2020; Efficacy of vonoprazan for initial and maintenance therapy in reflux esophagitis, nonerosive esophagitis, and proton pump inhibitor-resistant gastroesophageal reflux disease. Medicine (Baltimore). 99:e19520. DOI: 10.1097/MD.0000000000019520. PMID: 32176102. PMCID: PMC7440130.

21. Kim SH, Cho KB, Chun HJ, et al. 2021; Randomised clinical trial: comparison of tegoprazan and placebo in non-erosive reflux disease. Aliment Pharmacol Ther. 54:402–411. DOI: 10.1111/apt.16477. PMID: 34227708. PMCID: PMC8361733.

22. Yadlapati R, DeLay K. 2019; Proton Pump inhibitor-refractory gastroesophageal reflux disease. Med Clin North Am. 103:15–27. DOI: 10.1016/j.mcna.2018.08.002. PMID: 30466671. PMCID: PMC6260943.

23. Tsoukali E, Sifrim D. 2010; The role of weakly acidic reflux in proton pump inhibitor failure, has dust settled? J Neurogastroenterol Motil. 16:258–264. DOI: 10.5056/jnm.2010.16.3.258. PMID: 20680164. PMCID: PMC2912118.

24. Shinozaki S, Osawa H, Hayashi Y, et al. 2017; Vonoprazan treatment improves gastrointestinal symptoms in patients with gastroesophageal reflux disease. Kaohsiung J Med Sci. 33:616–622. DOI: 10.1016/j.kjms.2017.07.004. PMID: 29132551.

25. Jaynes M, Kumar AB. 2018; The risks of long-term use of proton pump inhibitors: a critical review. Ther Adv Drug Saf. 10:2042098618809927. DOI: 10.1177/2042098618809927. PMID: 31019676. PMCID: PMC6463334.

26. Umezawa M, Kawami N, Hoshino S, et al. 2018; Efficacy of on-demand therapy using 20-mg vonoprazan for mild reflux esophagitis. Digestion. 97:309–315. DOI: 10.1159/000485795. PMID: 29514137.

27. Asaoka D, Nagahara A, Hojo M, et al. 2017; Efficacy of a potassium-competitive acid blocker for improving symptoms in patients with reflux esophagitis, non-erosive reflux disease, and functional dyspepsia. Biomed Rep. 6:175–180. DOI: 10.3892/br.2016.828. PMID: 28357069. PMCID: PMC5351306.

28. Ivey KJ. 1988; Mechanisms of nonsteroidal anti-inflammatory drug-induced gastric damage. Actions of therapeutic agents. Am J Med. 84(2 Suppl 1):41–48. DOI: 10.1016/0002-9343(88)90253-7. PMID: 2894763.

29. Yu KS, Bae KS, Shon JH, et al. 2004; Pharmacokinetic and pharmacodynamic evaluation of a novel proton pump inhibitor, YH1885, in healthy volunteers. J Clin Pharmacol. 44:73–82. DOI: 10.1177/0091270003261321. PMID: 14681344.

30. Miwa H, Uedo N, Watari J, et al. 2017; Randomised clinical trial: efficacy and safety of vonoprazan vs. lansoprazole in patients with gastric or duodenal ulcers - results from two phase 3, non-inferiority randomised controlled trials. Aliment Pharmacol Ther. 45:240–252. DOI: 10.1111/apt.13876. PMID: 27891632. PMCID: PMC6680291.

31. Cho YK, Choi MG, Choi SC, et al. 2020; Randomised clinical trial: tegoprazan, a novel potassium-competitive acid blocker, or lansoprazole in the treatment of gastric ulcer. Aliment Pharmacol Ther. 52:789–797. DOI: 10.1111/apt.15865. PMID: 32701188. PMCID: PMC7496685.

32. Kawai T, Oda K, Funao N, et al. 2018; Vonoprazan prevents low-dose aspirin-associated ulcer recurrence: randomised phase 3 study. Gut. 67:1033–1041. DOI: 10.1136/gutjnl-2017-314852. PMID: 29196436. PMCID: PMC5969345.

33. Jung HK, Kang SJ, Lee YC, et al. Korean College of Helicobacter and Upper Gastrointestinal Research. Evidence-based guidelines for the treatment of Helicobacter pylori infection in Korea 2020. Gut Liver. 2021; 15:168–195. Korean College of Helicobacter and Upper Gastrointestinal Research. DOI: 10.5009/gnl20288. PMID: 33468712. PMCID: PMC7960974.

34. Scott D, Weeks D, Melchers K, Sachs G. 1998; The life and death of Helicobacter pylori. Gut. 43 Suppl 1:S56–60. DOI: 10.1136/gut.43.2008.S56. PMID: 9764042. PMCID: PMC1766596.

35. Graham DY, Lu H, Yamaoka Y. 2007; A report card to grade Helicobacter pylori therapy. Helicobacter. 12:275–278. DOI: 10.1111/j.1523-5378.2007.00518.x. PMID: 17669098.

36. Thung I, Aramin H, Vavinskaya V, et al. 2016; Review article: the global emergence of Helicobacter pylori antibiotic resistance. Aliment Pharmacol Ther. 43:514–533. DOI: 10.1111/apt.13497. PMID: 26694080. PMCID: PMC5064663.

37. Lyu QJ, Pu QH, Zhong XF, Zhang J. 2019; Efficacy and safety of vonoprazan-based versus proton pump inhibitor-based triple therapy for Helicobacter pylori eradication: a meta-analysis of randomized clinical trials. Biomed Res Int. 2019:9781212. DOI: 10.1155/2019/9781212. PMID: 31211144. PMCID: PMC6532346.

38. Jung YS, Kim EH, Park CH. 2017; Systematic review with meta-analysis: the efficacy of vonoprazan-based triple therapy on Helicobacter pylori eradication. Aliment Pharmacol Ther. 46:106–114. DOI: 10.1111/apt.14130. PMID: 28497487.

39. Chey WD, Mégraud F, Laine L, López LJ, Hunt BJ, Howden CW. 2022; Vonoprazan triple and dual therapy for Helicobacter pylori infection in the United States and Europe: randomized clinical trial. Gastroenterology. 163:608–619. DOI: 10.1053/j.gastro.2022.05.055. PMID: 35679950.

40. Choi YJ, Lee YC, Kim JM, et al. 2022; Triple therapy-based on tegoprazan, a new potassium-competitive acid blocker, for first-line treatment of Helicobacter pylori infection: a randomized, double-blind, phase iii, clinical trial. Gut Liver. 16:535–546. DOI: 10.5009/gnl220055. PMID: 35791797. PMCID: PMC9289827.

41. Kim JY, Lee SY, Kim H, Kim JH, Sung IK, Park HS. 2021; Efficacy of seven-day potassium-competitive acid blocker-based first-line Helicobacter pylori eradication therapy administered with bismuth. Yonsei Med J. 62:708–716. DOI: 10.3349/ymj.2021.62.8.708. PMID: 34296548. PMCID: PMC8298865.

42. Jung YS, Kim S, Kim HY, Noh SJ, Park JH, Park CH. 2022; 7-day versus 14-day tegoprazan-based triple therapy to treat Helicobacter pylori infection: real-world evidence. J Gastroenterol Hepatol. 37:1911–1918. DOI: 10.1111/jgh.15939. PMID: 35816283.

43. Tariq R, Singh S, Gupta A, Pardi DS, Khanna S. 2017; Association of gastric acid suppression with recurrent clostridium difficile infection: a systematic review and meta-analysis. JAMA Intern Med. 177:784–791. DOI: 10.1001/jamainternmed.2017.0212. PMID: 28346595. PMCID: PMC5540201.

44. Son M, Park IS, Kim S, et al. 2022; Novel potassium-competitive acid blocker, tegoprazan, protects against colitis by improving gut barrier function. Front Immunol. 13:870817. DOI: 10.3389/fimmu.2022.870817. PMID: 35693794. PMCID: PMC9174989.